294 related articles for article (PubMed ID: 33259087)
1. CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naïve oligometastatic prostate cancer.
Sheikhbahaei S; Reyes DK; Rowe SP; Pienta KJ
Prostate; 2021 Feb; 81(2):127-134. PubMed ID: 33259087
[TBL] [Abstract][Full Text] [Related]
2. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
Pan J; Chi C; Qian H; Zhu Y; Shao X; Sha J; Xu F; Wang Y; Karnes RJ; Dong B; Xue W
Urol Oncol; 2019 Dec; 37(12):991-998. PubMed ID: 31466813
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
[TBL] [Abstract][Full Text] [Related]
5. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
Damodaran S; Lang JM; Jarrard DF
J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
[TBL] [Abstract][Full Text] [Related]
6. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
Eastham JA; Heller G; Halabi S; Monk JP; Beltran H; Gleave M; Evans CP; Clinton SK; Szmulewitz RZ; Coleman J; Hillman DW; Watt CR; George S; Sanda MG; Hahn OM; Taplin ME; Parsons JK; Mohler JL; Small EJ; Morris MJ
J Clin Oncol; 2020 Sep; 38(26):3042-3050. PubMed ID: 32706639
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
[TBL] [Abstract][Full Text] [Related]
8. Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer.
Reyes DK; Rowe SP; Schaeffer EM; Allaf ME; Ross AE; Pavlovich CP; Deville C; Tran PT; Pienta KJ
Med Oncol; 2020 Jun; 37(7):60. PubMed ID: 32524295
[TBL] [Abstract][Full Text] [Related]
9. Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration.
Shigeta K; Kosaka T; Hongo H; Yanai Y; Matsumoto K; Morita S; Mizuno R; Shinojima T; Kikuchi E; Oya M
Int J Clin Oncol; 2019 May; 24(5):546-553. PubMed ID: 30604159
[TBL] [Abstract][Full Text] [Related]
10. UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castration-sensitive prostate cancer.
Mahler M; Al-Ezzi E; Shrem NS; Zhang L; Winquist E; Canil C; Ong M; Hansen AR; Emmenegger U
Urol Oncol; 2022 Dec; 40(12):539.e17-539.e22. PubMed ID: 36272847
[TBL] [Abstract][Full Text] [Related]
11. Effect of Upfront Docetaxel in De Novo Metastatic Castration-Sensitive Prostate Cancer Patients with Gleason Grade Group 5.
Yildirim S; Yilmaz C
J Coll Physicians Surg Pak; 2023 Nov; 33(11):1310-1314. PubMed ID: 37926887
[TBL] [Abstract][Full Text] [Related]
12. Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study.
Kwon WA; Joung JY; Lee JE; Choi SY; Kim SH; Seo HK; Lee KH; Kim CS
Investig Clin Urol; 2019 May; 60(3):195-201. PubMed ID: 31098427
[TBL] [Abstract][Full Text] [Related]
13. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
[TBL] [Abstract][Full Text] [Related]
14. Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia.
Stangl-Kremser J; Suarez-Ibarrola R; Andrea D; Korn SM; Pones M; Kramer G; Marhold M; Krainer M; Enikeev DV; Glybochko PV; Tamandl D; Shariat SF; Baltzer P
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):309-315. PubMed ID: 31745255
[TBL] [Abstract][Full Text] [Related]
15. Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective review.
Wu W; Liu X; Chaftari P; Cruz Carreras MT; Gonzalez C; Viets-Upchurch J; Merriman K; Tu SM; Dalal S; Yeung SC
PLoS One; 2015; 10(3):e0122047. PubMed ID: 25822612
[TBL] [Abstract][Full Text] [Related]
16. Psoas mass index at the level of the third lumbar vertebra on computed tomography is a prognostic predictor for metastatic castration-sensitive prostate cancer.
Owa S; Sasaki T; Ikadai R; Tabata Y; Takeuchi Y; Nishikawa T; Kato M; Higashi S; Sugino Y; Masui S; Nishikawa K; Inoue T
Int J Clin Oncol; 2024 Jun; 29(6):840-846. PubMed ID: 38587577
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous Fat Distribution is a Prognostic Biomarker for Men with Castration Resistant Prostate Cancer.
Lee JS; Lee HS; Ha JS; Han KS; Rha KH; Hong SJ; Chung BH; Koo KC
J Urol; 2018 Jul; 200(1):114-120. PubMed ID: 29366641
[TBL] [Abstract][Full Text] [Related]
18. Androgen Deprivation Therapy for Prostate Cancer Influences Body Composition Increasing Risk of Sarcopenia.
Korczak J; Mardas M; Litwiniuk M; Bogdański P; Stelmach-Mardas M
Nutrients; 2023 Mar; 15(7):. PubMed ID: 37049485
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous adipose tissue characteristics and the risk of biochemical recurrence in men with high-risk prostate cancer.
McDonald AM; Fiveash JB; Kirkland RS; Cardan RA; Jacob R; Kim RY; Dobelbower MC; Yang ES
Urol Oncol; 2017 Nov; 35(11):663.e15-663.e21. PubMed ID: 28797587
[TBL] [Abstract][Full Text] [Related]
20. Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer.
Marshall CH; Tunacao J; Danda V; Tsai HL; Barber J; Gawande R; Weiss CR; Denmeade SR; Joshu C
BJU Int; 2021 Sep; 128(3):366-373. PubMed ID: 33765326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
